ArticleTherapeutics and clinical risk management2009
The role of urate and xanthine oxidase in vascular oxidative stress: future directions.
Article in Therapeutics and clinical risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.Rheumatology international · 2014Trial
- The SLC-ome of membrane transport: from molecular discovery to physiology and clinical applications.Physiological reviews · 2026Review
- Uric Acid-to-HDL Cholesterol Ratio as an Independent Predictor of In-Hospital New-Onset Atrial Fibrillation in Non-ST-Elevation Myocardial Infarction.Journal of clinical medicine · 2026Article
- Oxidative Stress Biomarkers in Hypertension.Current medicinal chemistry · 2025Review
- The Effects of Antioxidant Supplementation on Soccer Performance and Recovery: A Critical Review of the Available Evidence.Nutrients · 2024Review
- Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress.Vaccines · 2023Review
- Altered Urinary Metabolomics in Hereditary Angioedema.Metabolites · 2022Article
- A neutrophil signature is strongly associated with increased cardiovascular risk in gout.Rheumatology (Oxford, England) · 2021Article
- Functions of ROS in Macrophages and Antimicrobial Immunity.Antioxidants (Basel, Switzerland) · 2021Review
- Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2.Clinical and experimental medicine · 2018Article
- Article
- Interplay between oxidant species and energy metabolism.Redox biology · 2016Review
- Article
- Essential hypertension and oxidative stress: New insights.World journal of cardiology · 2014Review
- Febuxostat for hyperuricemia in patients with advanced chronic kidney disease.Drug target insights · 2014Article
- Oxidative stress produced by xanthine oxidase induces apoptosis in human extravillous trophoblast cells.The Journal of reproduction and development · 2013Article
- Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular oxidative stress has been shown to be a potent factor in the pathophysiology of endothelial dysfunction. Despite current optimal evidence-based therapy, mortality from various cardiovascular disorders remains high. The search for newer, novel ways of attenuating endothelial dysfunction has yielded several new and exciting possibilities, one of which is the manipulation of urate levels using xanthine oxidase inhibitors. Agents such as allopurinol have shown marked improvements in vascular endothelial function in various cohorts at risk of cardiovascular events. Most of the evidence so far comes from smaller mechanistic studies. The few large randomized controlled trials have failed to show any significant mortality benefit using these agents. This article highlights the potential avenues of further research such as dose-response, and the potential for these agents to regress left ventricular hypertrophy. The role of newer agents such as febuxostat and oxypurinol are discussed as well as potential reasons why some of the current newer agents have failed to live up to the promising early-phase data. It is crucial that these remaining questions surrounding urate, xanthine oxidase and the role of various agents that affect this important oxidative stress-generating system are answered, and therefore these promising agents should not be discarded prematurely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.